MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Predictive Oncology Balance Sheet 2011-2026 | POAI
Annual Balance Sheet Predictive Oncology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
1.4 M | -6.15 M | -21.9 M | -27.3 M | 3.75 M | 5.37 M | 1.47 M | -766 K | -1.76 M | -4.86 M | 921 K | 178 K | 1.16 M | 1.56 M |
Long Term Debt |
1.56 M | 2.13 M | 86.1 K | 240 K | - | - | - | - | - | - | - | - | 89.3 K | 630 K |
Long Term Debt Current |
573 K | 445 K | 94.2 K | 640 K | 597 K | 459 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 236 K | 270 K | - | - | 310 K | - | 214 K | 343 K | 258 K | 796 K |
Total Current Liabilities |
3.59 M | 3.95 M | 3.88 M | 3.24 M | 9.34 M | 10.9 M | 3.66 M | 932 K | 1.57 M | 1.52 M | 6.2 M | 3.47 M | 3.41 M | 2.35 M |
Total Liabilities |
5.18 M | 6.15 M | 3.97 M | 3.51 M | 10.4 M | 11.1 M | 3.66 M | 932 K | 1.88 M | 1.52 M | 6.42 M | 3.81 M | 3.67 M | 3.15 M |
Deferred Revenue |
305 K | 302 K | 602 K | 187 K | 53 K | 40.4 K | 23.1 K | 6.66 K | 8 K | 5 K | 5 K | 69 K | - | - |
Retained Earnings |
-180 M | -168 M | -154 M | -128 M | - | -82.5 M | -63.1 M | -54.8 M | -47 M | -40.5 M | -35.6 M | -28.7 M | -19.3 M | -11.9 M |
Total Assets |
4.97 M | 14.4 M | 25.7 M | 43.8 M | 13.1 M | 22.4 M | 3.71 M | 3.62 M | 2.81 M | 5.63 M | 901 K | 593 K | 370 K | 446 K |
Cash and Cash Equivalents |
735 K | 8.73 M | 22.1 M | 28.2 M | 678 K | 151 K | 162 K | 766 K | 1.76 M | 4.86 M | 16.4 K | 102 K | 13.1 K | 123 K |
Book Value |
-203 K | 8.27 M | 21.8 M | 40.3 M | 2.64 M | 11.2 M | 53.5 K | 2.69 M | 924 K | 4.11 M | -5.52 M | -3.22 M | -3.3 M | -2.7 M |
Total Shareholders Equity |
-203 K | 8.27 M | 21.8 M | 40.3 M | 2.64 M | 11.2 M | 53.5 K | 2.69 M | 924 K | 4.11 M | -5.52 M | -3.22 M | -3.3 M | -2.7 M |
All numbers in USD currency
Quarterly Balance Sheet Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.08 M | 1.24 M | 1.41 M | 1.56 M | 1.7 M | 1.86 M | 2.03 M | 2.13 M | 2.34 M | - | - | 86.1 K | - | - | - | 240 K | - | - | - | 845 K | 845 K | 845 K | 845 K | 270 K | 270 K | 270 K | 270 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.3 K | 89.3 K | 89.3 K | 89.3 K | 630 K | 630 K | 630 K | 630 K |
Total Liabilities |
80.6 M | 5.09 M | 6.01 M | 5.18 M | 5.53 M | 6.49 M | 6.55 M | 6.15 M | 6.52 M | 6.26 M | 6.51 M | 3.97 M | 3.57 M | 2.96 M | 2.88 M | 3.51 M | 3.41 M | 3.82 M | 4.11 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 3.66 M | 3.66 M | 3.66 M | 3.66 M | 932 K | 932 K | 932 K | 932 K | 1.88 M | 1.88 M | 1.88 M | 1.88 M | 1.52 M | 1.52 M | 1.52 M | 1.52 M | 6.42 M | 6.42 M | 6.42 M | 6.42 M | 3.81 M | 3.81 M | 3.81 M | 3.81 M | 3.67 M | 3.67 M | - | - | - | - | - | - |
Deferred Revenue |
147 K | 149 K | 152 K | 224 K | 257 K | 270 K | 304 K | 302 K | 375 K | 628 K | 639 K | 602 K | 495 K | 531 K | 183 K | 187 K | 153 K | 154 K | 154 K | 53 K | 53 K | 53 K | 53 K | 40.4 K | 40.4 K | 40.4 K | 40.4 K | 23.1 K | 23.1 K | 23.1 K | 23.1 K | 6.66 K | 10.2 K | 14.2 K | 14.4 K | 8 K | 8 K | 8 K | 8 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 5 K | 69 K | 69 K | 69 K | 69 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-263 M | -185 M | -183 M | -180 M | -178 M | -175 M | -172 M | -168 M | -164 M | -161 M | -157 M | -154 M | -146 M | -142 M | -131 M | -128 M | -120 M | -115 M | -112 M | -108 M | -108 M | -108 M | -108 M | -82.5 M | -82.5 M | -82.5 M | -82.5 M | -63.1 M | -63.1 M | -63.1 M | -63.1 M | -53 M | -54.8 M | -54.8 M | -54.8 M | -47 M | -47 M | -47 M | -47 M | -40.5 M | -40.5 M | -40.5 M | -40.5 M | -35.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
3.14 M | 3.44 M | 5.87 M | 4.97 M | 7.5 M | 10.6 M | 10.6 M | 14.4 M | 18.2 M | 21 M | 25.1 M | 25.7 M | 33.2 M | 36.5 M | 25.7 M | 43.8 M | 51.2 M | 56.9 M | 39.7 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 22.4 M | 22.4 M | 22.4 M | 22.4 M | 3.71 M | 3.71 M | 3.71 M | 3.71 M | 3.62 M | 3.62 M | 3.62 M | 3.62 M | 2.81 M | 2.81 M | 2.81 M | 2.81 M | 5.63 M | 5.63 M | 5.63 M | 5.63 M | 901 K | 901 K | 901 K | 901 K | 593 K | 593 K | 593 K | 593 K | 370 K | 370 K | 370 K | 370 K | 446 K | 446 K | 446 K | 446 K |
Cash and Cash Equivalents |
182 K | 506 K | 3.09 M | 612 K | 2.96 M | 5.28 M | 4.73 M | 8.73 M | 11.9 M | 14.8 M | 18.6 M | 22.1 M | 25.4 M | 28.2 M | 25.1 M | 28.2 M | 41.8 M | 44.9 M | 27.3 M | 678 K | 678 K | 678 K | 678 K | 151 K | 151 K | 151 K | 151 K | 162 K | 162 K | 162 K | 162 K | 766 K | 766 K | 766 K | 766 K | 1.76 M | 1.76 M | 1.76 M | 1.76 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 16.4 K | 16.4 K | 16.4 K | 16.4 K | 102 K | 102 K | 102 K | 102 K | 13.1 K | 13.1 K | 13.1 K | 13.1 K | 123 K | 123 K | 123 K | 123 K |
Book Value |
-77.4 M | -1.65 M | -146 K | -203 K | 1.97 M | 4.09 M | 4.05 M | 8.27 M | 11.7 M | 14.7 M | 18.6 M | 21.8 M | 29.6 M | 33.5 M | 22.9 M | 40.3 M | 47.8 M | 53.1 M | 35.5 M | 2.64 M | 2.64 M | 2.64 M | 2.64 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 53.5 K | 53.5 K | 53.5 K | 53.5 K | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 924 K | 924 K | 924 K | 924 K | 4.11 M | 4.11 M | 4.11 M | 4.11 M | -5.52 M | -5.52 M | -5.52 M | -5.52 M | -3.22 M | -3.22 M | -3.22 M | -3.22 M | -3.3 M | -3.3 M | 370 K | 370 K | 446 K | 446 K | 446 K | 446 K |
Total Shareholders Equity |
-77.4 M | -1.65 M | -146 K | -203 K | 1.97 M | 4.09 M | 4.05 M | 8.27 M | 11.7 M | 14.7 M | 18.6 M | 21.8 M | 29.6 M | 33.5 M | 37.2 M | 40.3 M | 47.8 M | 53.1 M | 35.5 M | 2.64 M | 2.64 M | 2.64 M | 2.64 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 53.5 K | 53.5 K | 53.5 K | 53.5 K | 2.69 M | 2.69 M | 2.69 M | 2.69 M | 924 K | 924 K | 924 K | 924 K | 4.11 M | 4.11 M | 4.11 M | 4.11 M | -5.52 M | -5.52 M | -5.52 M | -5.52 M | -3.22 M | -3.22 M | -3.22 M | -3.22 M | -3.3 M | -3.3 M | -3.3 M | -3.3 M | -2.7 M | -2.7 M | -2.7 M | -2.7 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Predictive Oncology , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B |  USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
AtriCure
ATRC
|
$ 31.07 | -1.26 % | $ 1.48 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
The Cooper Companies
COO
|
$ 81.93 | -1.73 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 84.0 | 1.13 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.9 | 9.0 % | $ 26.4 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
$ 19.1 | 0.45 % | $ 9.8 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 115.62 | -1.86 % | $ 5.6 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 64.55 | -1.59 % | $ 3.25 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.57 | 4.25 % | $ 198 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 127.87 | 1.61 % | $ 4.09 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.88 | 2.2 % | $ 223 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.58 | 2.14 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 106.91 | -0.87 % | $ 2.42 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 171.22 | -1.8 % | $ 49.3 B | USA |
 |
Masimo Corporation
MASI
|
$ 175.43 | 0.04 % | $ 9.35 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.47 | 3.28 % | $ 25.2 M |  Israel |
 |
AngioDynamics
ANGO
|
$ 10.98 | -0.54 % | $ 449 M | USA |
 |
BioLife Solutions
BLFS
|
$ 20.59 | 2.06 % | $ 949 M | USA |
 |
Nephros
NEPH
|
$ 3.92 | 1.29 % | $ 40.7 M | USA |
 |
electroCore
ECOR
|
$ 7.9 | 3.81 % | $ 43.6 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 28.51 | -0.52 % | $ 4.79 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.68 | -3.05 % | $ 20.4 M | USA |
 |
ICU Medical
ICUI
|
$ 142.18 | -0.34 % | $ 3.5 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 501.88 | 0.9 % | $ 179 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 18.29 | 1.89 % | $ 1.23 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 74.53 | -0.43 % | $ 4.41 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Repligen Corporation
RGEN
|
$ 126.05 | 2.43 % | $ 7.02 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | 0.67 % | $ 223 M | USA |
 |
ResMed
RMD
|
$ 258.94 | 0.22 % | $ 37.8 B | USA |
 |
Pro-Dex
PDEX
|
$ 48.51 | 2.1 % | $ 159 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.17 | 1.32 % | $ 950 M | USA |
 |
STERIS plc
STE
|
$ 244.67 | 0.62 % | $ 24.1 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 119.41 | -2.24 % | $ 5.33 B | USA |
 |
Stereotaxis
STXS
|
$ 2.22 | 3.74 % | $ 179 M | USA |
 |
Utah Medical Products
UTMD
|
$ 67.17 | 0.99 % | $ 244 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 250.46 | -0.3 % | $ 18.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 13.47 | 1.24 % | $ 2.69 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 2.33 % | $ 23.1 M | USA |